^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tri-Ad5

    i
    Other names: Tri-Ad5, Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5, Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5
    Associations

    News

    Trials
    Company:
    ImmunityBio, National Cancer Institute - Bethesda
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    6d
    Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet). (PubMed, Front Immunol)
    In LS carriers without active cancer, the combination of Tri-Ad5 + NAI was well-tolerated; the RCT phase is ongoing. https://clinicaltrials.gov/study/, identifier NCT05419011.
    Clinical • P2b data • Journal
    |
    MUC1 (Mucin 1) • IL15 (Interleukin 15)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    11ms
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    1year
    Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection. (PubMed, Oncologist)
    In this small study, Tri-Ad5 vaccine plus bintrafusp alfa resulted in CPD in 2/6 patients. Participants also had favorable 2-year RFS compared to historical values. Ongoing tissue and peripheral immunome analyses may provide mechanistic insight. (ClincalTrials.gov Identifier: NCT04247282; IRB Approved.).
    Journal
    |
    MUC1 (Mucin 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    bintrafusp alfa (M7824) • ETBX-011 • ETBX-051 • ETBX-061 • Tri-Ad5
    over1year
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2027 --> Jan 2028 | Trial primary completion date: Feb 2027 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    almost2years
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2027 --> Feb 2027
    Trial completion date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    almost2years
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2027 --> Jul 2027
    Trial completion date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    over2years
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Recruiting, National Cancer Institute (NCI) | Phase classification: P2b --> P2
    Phase classification
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    3years
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2b, N=186, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Aug 2023 --> Mar 2023
    Enrollment open • Trial initiation date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    3years
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2b, N=186, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Feb 2027 | Initiation date: Nov 2022 --> Aug 2023 | Trial primary completion date: Oct 2026 --> Feb 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5